



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 4 : G01N 21/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 88/ 08528 (43) International Publication Date: 3 November 1988 (03.11.88)</p>
<p>(21) International Application Number: PCT/US88/01432 (22) International Filing Date: 2 May 1988 (02.05.88) (31) Priority Application Number: 044,767 (32) Priority Date: 1 May 1987 (01.05.87) (33) Priority Country: US (71) Applicant: BIOTRONIC SYSTEMS CORPORATION [US/US]; 15225 Shady Grove Rd., Suite 306, Rockville, MD 20806 (US). (72) Inventors: STANBRO, William, D. ; 10916 Battersea Lane, Columbia, MD 21044 (US). HUNTER, Kenneth, W., Jr. ; 8600 Fox Run, Potomac, MD 20854 (US). NEWMAN, Arnold, L. ; 4128 Warner Street, Kensington, MD 20895 (US).</p>		<p>(74) Agents: POJUNAS, Leonard, W., Jr. et al.; Indyk, Pojunas & Brady, Suite 409, 2001 Jefferson Davis Highway, Arlington, VA 22202 (US). (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: ADDED ARRAY OF MOLECULAR CHAINS FOR INTERFERING WITH ELECTRICAL FIELDS</p> <div data-bbox="500 1205 1214 1709"> </div> <p>(57) Abstract</p> <p>An array of molecular chains (24, 26) is added to a dielectric material between two electrodes (12, 14) of a capacitive affinity sensor (10). Such an array of molecular chains (24, 26) greatly changes dielectric properties between the two electrodes (12, 14) to greatly enhance sensitivity of the sensor (10). In a sensor (10) using direct binding, a viral fragment (36) is bound to the sensor's surface (34). A molecular chain, comprising an anti-viral antibody (38), an anti-human antibody (40), and a protein molecule (42), binds to the viral fragment (36). In a sensor (10) using competitive binding a hapten (52) is bound to the sensor's surface (34). A molecular chain, comprising an antibody (54) with attached aliphatic hydrocarbons (56), binds to the hapten (52). A free analyte (60) competes with the hapten (52) to bind with the antibody (54).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

ADDED ARRAY OF MOLECULAR CHAINS FOR
INTERFERING WITH ELECTRICAL FIELDS

Background of the Invention

Cross reference is made to two U.S. Patent
5 Applications: Serial Number 044,761, for Three
Dimensional Binding Site Array For Interfering With An
Electrical Field, by W.D. Stanbro; and Serial Number
044,767, for Sintered Pellet With Biochemically Active
Layer, by A.L. Newman, which were filed the same date and
10 were assigned to the same entity as this application.

The invention relates to a means for interfering with
an electrical field. More specifically, the invention
relates to an electrode insulated with an added array of
molecular chains.

15 In composition analysis, capacitive sensors have been
used to determine the concentration of a specific gas in a
mixture, or an analyte in a fluid, for example. Such
sensors measure a capacitance that changes with that
concentration.

20 Newman U.S. Patent Application Serial No. 799,761,
filed November 19, 1985, ("the Newman Patent Application")
involves a capacitor for determining the concentration of
an analyte in a fluid, for instance. Biospecific binding
reactions occur in a space between electrodes of a
25 capacitive sensor. These reactions occur among molecules
of a binding agent immobilized on a surface and an analyte
in a fluid. These reactions result in the displacement of
small fluid molecules having high dielectric constants by
large biochemical molecules having low-dielectric
30 constants. This displacement of molecules changes the
dielectric properties of the capacitor.

Raymond et al. U.S. Patent 4,571,543 discusses a
capacitor for detecting and measuring the concentration of
specific non-aqueous materials or constituents in fluids.
35 The capacitor is layered with a coating of silane and then
a coating of certain polymers. These polymers form

SUBSTITUTE SHEET

-2-

membranes that are permeable to constituents of the fluids. The constituents penetrate through the membrane to change the dielectric constant of a solution in the membrane.

5 Volgyesi U.S. Patent 4,453,126 concerns a capacitor for monitoring the concentration of anaesthetic gas in a breathing mixture. The capacitor has a dielectric of lipids or elastomers which permit the absorption of the anaesthetic gas to vary electrical characteristics of the
10 sensor.

"Adsorption Of Blood Proteins On Metals Using Capacitance Techniques", by Stoner et al., The Journal of Physical Chemistry, Vol. 74, No. 5, March 5, 1970, describes a differential capacity method for measuring
15 adsorption of proteins on solid metal electrodes.

Arwin et al. U.S. Patent 4,072,576 relates to a capacitive method for studying enzymatic activity and for studying an immunological reaction. An adsorbed polypeptide substrate is used in studying enzymatic
20 activity and an antigen is adsorbed onto an electrode surface in studying the reaction of the antigen with an antibody.

Summary of the Invention

The invention concerns an apparatus, and a method for
25 making the apparatus, comprising a base layer, an electrical field generating means on the base layer, and an electrical field interfering means. The electrical field interfering means has a biochemically active layer comprising an antigen or an antibody, and a molecular
30 chain that extends from the biochemically active layer, for instance. In one version, the molecular chain comprises another antibody and a protein molecule. In another version, the molecular chain comprises an alkyl or an amide molecule.

35 In a specific embodiment, the electrical field generating means is an electrode of a capacitive affinity

-3-

sensor, for instance. In this embodiment, the biochemically active layer is part of a dielectric material between electrodes of the sensor, where the molecular chains bind. Thus, the thickness of the dielectric material greatly increases and the capacitance of the biochemically active layer greatly decreases. Such a biochemically active layer is used to provide a very sensitive capacitive affinity sensor, for instance.

Brief Description of the Figures

Figure 1 shows electrodes of a capacitive affinity sensor with a dielectric material according to this invention.

Figure 2 schematically shows direct binding of an array of molecular chains according to this invention.

Figure 3 shows another version of the molecular chain of Figure 2.

Figure 4 shows competitive binding of an array of molecular chains.

Figures 5 and 6 show examples of molecular chains for a competitive binding array.

Detailed Description

Capacitive affinity sensors measure the concentration of an analyte by detecting a change in capacitance as an analyte molecule moves in or out of an electric field between two electrodes of the sensor, for instance. The moving analyte molecule has a low dielectric constant and displaces solvent molecules having higher dielectric constants from a biochemically active layer between the two electrodes. The displacement of the the solvent molecules by the analyte molecules reduces capacitance between the two electrodes. The capacitance between the two electrodes is inversely proportional to the concentration of the analyte being measured by such a sensor.

Other capacitances are present in a capacitive affinity sensor and include the capacitance of any

-4-

passivating layers over the electrodes and the capacitance of the solvent about the electrodes. The capacitances of the sensor add as follows:

$$C_T = \frac{1}{\sum_{i=1}^n \frac{1}{C_i}} \quad (1)$$

where C_T is the total capacitance of the sensor and C_i is the capacitance of each of the biochemically active layer, the passivating layer and of the solvent. For an idealized parallel plate capacitor, the individual capacitances are proportional to the ratio of the dielectric constant and the distance between the parallel plates. That is

$$C_i = \frac{\epsilon_i}{d_i} \quad (2)$$

where ϵ_i is the dielectric constant and d_i is the distance between the parallel plates. This type of situation applies regardless of the actual geometry of the plates.

A passivating layer of a capacitive affinity sensor is about 2000 Angstroms thick and provides an impervious pin hole free barrier to water and ions. A solvent layer can be several microns thick. However, in a sensor as discussed in the Newman Patent Application, antibodies extend about 100 Angstroms above an insulator surface in the biochemically active layer. Thus, such a biochemically active layer is thin compared to the passivating layer and the solvent layer.

According to equation (2), the capacitance of such a thin, biochemically active layer is large compared to that of any passivating and solvent layers. According to equation (1), the dominant capacitance in the total capacitance C_T is that of the layer having the lowest capacitance. Thus, it is desirable to minimize the capacitance of the layer of an affinity sensor that is modulated, such as the biochemically active layer, to

-5-

maximize the sensitivity of such a sensor. Minimizing the capacitance of the biochemically active layer brings the capacitance of this layer into the ranges of the other capacitances in the sensor.

5 According to equation (2), capacitance of the biochemically active layer decreases with a decrease in the dielectric constant of the layer or an increase in the thickness of the layer. The inventors have recognized that this capacitance is also affected by any molecules
10 that might bind to the biochemically active layer, and that larger, low dielectric analyte molecules will displace a greater amount of the high dielectric solvent. The inventors have, therefore, developed a means for increasing the thickness of the dielectric material of a
15 capacitive affinity sensor by binding large molecular chains to a biochemically active layer between electrodes of that sensor. The large molecular chains bind and displace a greater amount of solvent, which increases the difference between capacitances that are measured when all
20 the molecular chains enter the electric field and when all leave the electric field.

Figure 1 shows schematically a capacitive affinity sensor 10 with electrodes 12 and 14 insulated according to this invention. The sensor 10 has a base layer 16 that
25 supports the two electrodes 12 and 14, which have opposite polarities. The base layer 16 comprises a substrate of insulating material like alumina.

A passivating layer 20 covers the base layer 16 and electrodes 12 and 14 in the preferred embodiment of this
30 invention. The passivating layer 20 protects the electrodes 12 and 14 from water and ions in a solvent 28.

Molecules form receptors 22 that extend from the passivating layer 20. These receptors 22 form a layer that is biochemically active. Each receptor 22 of this
35 layer is a potential binding site for a molecule of a

SUBSTITUTE SHEET

-6-

specific analyte 24. Also, molecules of the analyte 24 can be displaced, as described below.

The receptors 22 can comprise an antibody and the analyte 24 can comprise a bacteria, for instance. In
5 another version, the receptors 22 can comprise antigens and the analyte 24 can comprise an antibody. Though not shown, the receptors 22 also extend horizontally from any vertical surfaces covered by the passivating layer 20.

Large molecules 26 bind to the analyte 24. The large
10 molecule 26 may comprise a protein, for instance. The analyte 24 and the large molecules 26 form large molecular chains that bind to the receptor 22 as an added array in an electric field 30 between the electrodes 12 and 14. These large molecular chains have low dielectric constants
15 and displace a great amount of high dielectric constant solvent 28 from the electric field 30. These large molecular chains bind as an array that greatly increases the thickness d_i of the dielectric material in a capacitive affinity sensor and greatly changes the
20 dielectric properties of that sensor. According to equation (1), the capacitance between electrodes 12 and 14 greatly decreases.

Figure 1 shows molecular chains adjacent the electrodes 12 and 14. The molecular chains are adjacent
25 the electrodes 12 or 14 when the molecular chains substantially interfere with the electric field of such an electrode.

Figures 2 and 3 show embodiments of the invention which are ideal for a capacitive affinity sensor using
30 direct binding. A capacitive affinity sensor using direct binding is described in the Newman Patent Application.

Figure 2 schematically shows a detail of one array of large molecular chains 32. A sensor surface 34 comprises the base layer 16 and the passivating layer 20 of Figure
35 1. A viral fragment 36 extends from the sensor surface 34 in a biochemically active layer, and is one example of the


-7-

receptor molecule 22 of Figure 1. A human anti-viral antibody 38 is an example of an analyte in the solvent 28 and is biospecific to the viral fragment 36 to bind to that fragment. An anti-human antibody 40, from a non-
 5 human animal, and a bound protein molecule 42 are added to the solvent 28. Such a protein molecule 42 has a molecular weight on the order of one million.

The anti-human antibody 40 is an antibody to the human anti-viral antibody 38. A number of anti-human
 10 antibodies 40 bind to each human anti-viral antibody 38. Antibodies 38 and 40, and protein molecule 42 form a large molecular chain that binds to the viral fragment 36 on the sensor surface 34. In another version, the viral fragment 36 can also comprise a hapten that is biospecific to the
 15 human anti-viral antibody 38.

In this version of the invention, a protein molecule 42, such as thyroglobulin, is bound to the anti-human antibody 40 before both are added to the solvent 28. Thyroglobulin binds to the anti-human antibody 40 through
 20 a linker group, such as succinic acid, in a solvent of phosphate buffered saline having a pH of 6.4. 1-ethyl-3-(3)-dimethylaminopropyl (carbodiimide), known as EDC, catalyses a reaction in the solvent. Through this reaction, two carboxylic acid groups on the succinic acid
 25 bind to amine groups of the antibody 40 and of the thyroglobulin. This forms an amide linkage between the antibody 40 and the thyroglobulin. Dialysis against the phosphate buffered saline recovers the thyroglobulin and bound antibody 40.

30 The chemical formula:



35

SUBSTITUTE SHEET

-8-

illustrates this procedure. Ab represents the antibody
40.

Many such large molecular chains form an array that
is adjacent a single electrode 12 or 14 of Figure 1. Such
5 an array of large molecular chains forms an electrical
insulator against the electric field of that single
electrode. However, in a preferred version, the array of
large molecular chains bind through an analyte molecule of
that chain to a receptor as part of a dielectric material
10 between the two electrodes 12 and 14 of the affinity
sensor 10 of Figure 1, for instance.

The molecular chains 32 are very large, have low
dielectric constants, and, therefore, displace a great
amount of the solvent 28 which has a high dielectric
15 constant. The dielectric properties of such a sensor vary
greatly with the concentration of analyte molecules, such
as the antiviral antibody 38, in the solvent 28.

Figure 3 shows another version of the invention shown
in Figure 2. An antibody 44 is bound directly to the
20 sensor surface 34. Such antibodies 44 form a
biochemically active layer and are biospecific to an
analyte 46, like a bacteria, in the solution 28. The
analyte 46 diffuses through the solution 28 until the
analyte 46 binds to the antibody 44. Another antibody 48
25 and a bound protein molecule 50 diffuse through the
solution 28 and bind atop the analyte 46. The protein
molecule 50 is covalently bound to the second antibody 48
before both are added to the solution 28. These
antibodies 44 and 48 can be different or the same, though
30 each will bind to the analyte 46 through individual
epitopes of this bacteria.

The antibody 48, analyte 46 and protein 50 molecules
form a large molecular chain 32 that binds to the antibody
44 on the sensor surface 34. Such a large molecular chain
35 is added in an array that interferes with the electrical

-9-

field of the electrode 12 or 14 of Figure 1, for instance.

Figure 4 shows another embodiment of the invention which is ideal for a capacitive affinity sensor using competitive binding. A capacitive affinity sensor using competitive binding is described in the Newman Patent Application.

A hapten 52 is an example of a receptor molecule 22 and is bound directly to the sensor surface 34. Such hapten 52 form a biochemically active layer. An antibody 54 is biospecific to and binds to the hapten 52. According to the invention, a number of aliphatic hydrocarbons or alkyl molecules 56 extend from each antibody 54.

A large molecular chain 58 comprises an antibody 54 and the alkyl molecules that extend from that antibody. This large molecular chain 58 binds to the hapten 52 of the biochemically active layer of hapten 52. Such large molecular chains 58 bind in an array as part of the dielectric material in a capacitive affinity sensor, adjacent the electrodes 12 and 14 of Figure 1, for instance. A high dielectric constant solvent 28 covers each low dielectric constant molecular chain 58.

A free analyte 60 is introduced into the solvent 28. The analyte 60 diffuses toward the sensor surface 34. The antibodies 54 are biospecific, not only to the hapten 52, but also to the analyte 60. Thus, the hapten 52 and the analyte 60 compete to bind with an antibody 54 of a large molecular chain 58. As a result, these large molecular chains 58 diffuse through the solvent 28 away from the sensor surface 34 to bind with the free analyte 60. The amount of molecular chains 58 that diffuse through the solvent 28 from hapten 52 is proportional to the concentration of the free analyte 60 in the solvent 28.

A large volume of high dielectric constant solvent 28 replaces the low dielectric constant molecular chains 58

SUBSTITUTE SHEET

-10-

that diffuse from the sensor surface 34. In this way, the capacitance greatly increases between the two electrodes 12 and 14 of Figure 1, for instance.

5 Figure 5 shows a large amide molecular chain for use in the embodiment of Figure 4. Figure 5 shows an aliphatic hydrocarbon 62 extending from an antibody 64 through EDC catalyzed acylation of an amine. As an example of an aliphatic hydrocarbon 62, a decyl amide
10 extends from the antibody 64. This amide extends through its carboxylic functional group from the terminal end of an amine group molecule, like a peptide, of the antibody 64. Instead of the peptide, the amide can bind to the side chain $(CH_2)_4NH$ of a lysine molecule in the antibody
15 64, for instance.

The aliphatic hydrocarbon 62 binds to the antibody 64 to form a large molecular chain, according to the following procedure. First, the antibody 64 is placed in a solution of phosphate buffered saline having a pH of
20 6.4. Next, EDC and decanoic acid are added to the solution. Decanoic acid is commercially available from Aldrich, No. 15,376-1. The antibody, saline, EDC, and acid may be added together in any order. After the solution reacts, the derivatized antibody is recovered by
25 dialysis against the phosphate buffered saline to remove unreacted substances, byproducts and reagents from the solution.

The chemical formula

30
$$Ab-NH_2 + CH_3(CH_2)_8COOH \xrightarrow{EDC} Ab-NH-CO(CH_2)_8CH_3$$
 illustrates this procedure. $Ab-NH_2$ represents the antibody 64 with part of an amino group, like the terminal end of a peptide, extending from the antibody 64.

Figure 6 shows a large alkyl molecular chain for use
35 in the embodiment of Figure 4. Specifically, Figure 6 shows an alkyl group, hexcyl group molecule 66, extending

SUBSTITUTE SHEET

-11-

from the antibody 64 through reductive alkylation. As an example, a ketone, like the 2-hexanone of Figure 6, is bound to the terminal end of an amino group, like a peptide, of the antibody 64. Instead of the peptide, the
 5 ketone can bind to the side chain of a lysine molecule of the antibody. Also, instead of the ketone, an aldehyde can bind to a peptide or a lysine molecule of the antibody.

The alkyl group molecule 66 binds to the antibody 64
 10 to form a large molecular chain according to the following procedure. First, the antibody is placed in a solution of phosphate buffered saline at 0 degrees Centigrade with 0.1% ethylenediaminetetraacetic acid (EDTA) and solid sodium cyanoborohydride is added as a reducing agent.
 15 Next, 2-hexanone is slowly added to the solution and is gently stirred. 2-hexanone is commercially available from Aldrich, No. 10,300-4. After the solution has reacted, the derivatized antibody is recovered by dialysis against the phosphate buffered saline to remove unreacted
 20 substances, byproducts and reagents from the solution. The chemical formula

$$\text{Ab-NH}_2 + \text{CH}_3\text{CO}(\text{CH}_2)_3\text{CH}_3 \xrightarrow{\text{NaCNBH}_3} \text{Ab-NH-CH}(\text{CH}_3)((\text{CH}_2)_3\text{CH}_3)$$

illustrates this procedure. Ab-NH₂ represents the
 25 antibody 64 with part of an amino group, like the terminal end of a peptide, extending from the antibody.

According to the preferred version of this invention, molecular chains add in an array to a biochemically active layer. This array thickens a dielectric material of a
 30 capacitive affinity sensor and drastically affects the dielectric properties of the sensor. The array enhances the sensitivity of the sensor to an analyte in a solution, for example.

35

-12-

What is claimed is:

1. An apparatus comprising:
 - a base;
 - a means on the base for generating an electrical
 - 5 field; and
 - a means for interfering with the electrical field comprising a biochemically active layer, and a molecular chain extending from the biochemically active layer.
2. The apparatus of claim 1; a biochemically active layer comprising a receptor molecule bound to the base, and the molecular chain comprising an antibody that is biospecific to the receptor molecule.
3. The apparatus of claim 2, the molecular chain comprising a protein molecule bound to the antibody.
4. The apparatus of claim 2, the molecular chain comprising a second antibody that is an antibody to the first antibody.
5. The apparatus of claim 4, the molecular chain comprising a protein molecule bound to the second antibody.
6. The apparatus of claim 1, the biochemically active layer comprising a first antibody bound to the base, and the molecular chain comprising a second antibody.
7. The apparatus of claim 6, the molecular chain also comprising an antigen biospecific to the first antibody and to the second antibody.
8. The apparatus of claim 7, the molecular chain comprising a protein molecule bound to the second antibody.
9. The apparatus of claim 8, the first and second antibodies comprising different antibodies.
10. The apparatus of claim 2, the molecular chain comprising an alkyl group molecule bound to the antibody.
11. The apparatus of claim 2, the molecular chain comprising an amide group molecule bound to the antibody.

SUBSTITUTE SHEET

-13-

12. The apparatus of claim 1 comprising a capacitive affinity sensor;

the means for generating comprising two electrodes between which the electric field is generated;

5 the biochemically active layer comprising a dielectric material between the two electrodes.

13. The apparatus of claim 12, the dielectric material comprising a receptor molecule, the molecular chain comprising a protein bound to an antibody that is biospecific to the receptor molecule.

14. The apparatus of claim 12, the dielectric material comprising a receptor molecule, the molecular chain comprising: a first antibody that is biospecific to the receptor molecule, a second antibody that is an antibody
5 to the first antibody, and a protein bound to the second antibody.

15. The apparatus of claim 12, the dielectric material comprising a first antibody, the molecular chain comprising: an antigen that is biospecific to the first antibody; a second antibody that is biospecific to the
5 antigen; and a protein bound to the second antibody.

16. The apparatus of claim 12, the dielectric material comprising a receptor molecule, the molecular chain comprising an alkyl group molecule bound to an antibody that is biospecific to the receptor molecule.

17. The apparatus of claim 12, the dielectric material comprising a receptor molecule, the molecular chain comprising an amide group molecule bound to an antibody that is biospecific to the receptor molecule.

-14-

18. A method comprising:
positioning a means for generating an electrical
field on a base;
layering a biochemically active layer on the base
5 adjacent the electrical field generating means; and
binding a molecular chain to the biochemically active
layer.
19. The method of claim 18 comprising layering the
biochemically active layer as a dielectric material
between two electrodes of a capacitive affinity sensor.
20. The method of claim 19 comprising forming the
molecular chain with a first antibody and a protein.
21. The method of claim 20 comprising forming the
molecular chain with a second antibody that is an antibody
to the first antibody.
22. The method of claim 19 comprising layering an
antibody as the biochemically active layer and forming the
molecular chain with a second antibody and an antigen that
is biospecific to the first and second antibodies.
23. The method of claim 19, comprising forming the
molecular chain with an antibody and an alkyl group
molecule.
24. The method of claim 23 comprising forming the
molecular chain by acylating amines.
25. The method of claim 19 comprising forming the
molecular chain with an antibody and an aliphatic
hydrocarbon.
26. The method of claim 25 comprising forming the
molecular chain through reductive alkylation.




FIG. 1




FIG. 2




FIG. 3




FIG. 5





FIG. 6

FIG. 4



INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US88/01432**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (4): G01N 21/00 U.S. CL.: 422/68		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	436/525, 528, 805, 806, 807, 822-825; 422/68, 69, 83, 90, 98 324/60.R, 61.R, 61.C, 71.R; 435/817, 288, 291; 204/403.	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y, P	US, A, 4,713,347 (MITCHELL ET AL.), 15 Dec. 1987, See entire document.	1-26
A	US, A, 4,637,861 (KRULL ET AL.), 20 Jan. 1987, See entire document.	1-26
A	US, A, 4,571,543 (RAYMOND ET AL.), 18 Feb. 1986, See entire document.	1-26
Y	US, A, 4,562,157 (LOWE ET AL.), 31 Dec. 1985, See entire document.	1-26
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
26 JULY 1988	01 SEP 1988	
International Searching Authority	Signature of Authorized Officer	
ISA/US	 T.J. WALLEN	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	US, A, 4,490,216 (McCONNEL), 25 Dec. 1984, See entire document.	1-26
A	US, A, 4,453,126 (VOLGYESI), 05 Jun. 1984, See entire document.	1-26
A	US, A, 4,444,892 (MALMROS), 24 Apr. 1984, See entire document.	1-26
A	US, A, 4,387,369 (KLEIN ET AL.), 07 June 1983, See entire document.	1-26
A	US, A, 4,350,660 (ROBINSON ET AL.), 21 Sep. 1982, See entire document.	1-26
A	US, A, 4,243,751 (SWARTZ), 06 Jan. 1981, See entire document.	1-26
A	US, A, 4,072,576, (ARWIN ET AL.), 07 Feb. 1987, See entire document.	1-26
A	US, A, 3,999,122 (WINSTEL ET AL), 21 Dec. 1976, See entire document.	1-26

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)